Treating Patients as Individuals
"Oftentimes, we forget that not every patient can be treated the same. There are patients who have allergies to dyes and/or fillers, in addition to those who may have difficulty taking commercially available medications. For those patients, compounding is the answer. It allows us to work with the patient and the physician to prepare medications that are tailored to meet patient-specific needs so no patient is left behind". In addition to compounding, Stone Oak Pharmacy also offers retail pharmacy services, disease state consultations, durable medical equipment (DME), immunizations, and delivery services.

Certifications:
Board Certified for the Administration of Immunizations of Vaccines under Written Protocol of a Physician; Certified in Compounding Techniques from the Professional Compounding Centers of America; Certified in Quality Assessment, Quality Control, and Quality Assurance from the Professional Compounding Centers of America

Compounding Training:
Comprehensive compounding experience since 2000; Bio-Identical HRT Symposium, BHRT for Female Patients Symposium, Veterinary Symposium

Education
Pharm.D. (Doctor of Pharmacy), University of Texas at Austin;
BS, Biology, University of Texas at San Antonio

Member:
Professional Compounding Centers of America (PCCA)

Research:
Involved in binding and preparing the medication prior to patient administration.
1) A pilot, randomized, double-blind, placebo-controlled, multicenter study of the safety and efficacy of combination intrathecal ziconotide (Prialt) and morphine (Infumorph): Addition of Prialt or Placebo in Patients Receiving Intrathecal Infumorph for Severe Chronic Pain. (Protocol No. ELN92045-205)

2) An exploratory, double-blind, randomized, placebo-controlled study evaluating topical recombinant human vascular endothelial growth factor (Telbermin) for induction of healing chronic, diabetic foot ulcers (Protocol No. VGF2763g)

3) A randomized, double-blind, placebo-controlled, multicenter, multiple dose, sequential dose escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of NBI-6024 in adult and adolescent patients with insulin-dependent type-1 diabetes mellitus (Protocol No. NBI-6024-0003)